• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Why Biopharmaceutical Dynavax Technologies Could Soar in 2022

Here's how traders can play the stock.
By BRUCE KAMICH
Sep 24, 2021 | 07:45 AM EDT
Stocks quotes in this article: DVAX

During Thursday's Mad Money Lightning Round segment host Jim Cramer fielded questions about stocks from various callers. One caller asked Cramer about Dynavax Technologies (DVAX) . "It's good. I love these little drug stories," responded Cramer.

Let's check out the charts of this biopharmaceutical company that develops and commercializes novel vaccines.

In the daily bar chart of DVAX, below, we can see two base patterns that have supported the rally so far. On the far left hand side of the chart is a sideways pattern around $4 followed by a breakout and rally to the $10 area. For six months DVAX trades around the $10 area and then breaks out for a rally to $20. Prices are trading above the rising 50-day moving average line and the rising 200-day line.

It is hard to see what the trading volume has been doing on this chart but the On-Balance-Volume (OBV) line has moved in a positive direction and confirms and supports the price gains this year. The Moving Average Convergence Divergence (MACD) oscillator is crossing to the upside for a fresh outright buy signal.

 
In the weekly Japanese candlestick chart of DVAX, below, we can see that the shares made a three-year saucer-like base pattern. Students of technical analysis may want to read my book on chart patterns which are still working after 110 years. Prices bottomed out in the $4-$2 area but the "neckline" around $12 is interesting and hard to miss. This large base pattern can support further gains in the months ahead, I believe. The rising 40-week moving average line tells us that math is on our side.
 
The rising OBV line from the middle of the base is just what the doctor ordered -- more traders are getting involved and buyers are more aggressive. The MACD oscillator has been above the zero line all year.
 
 
In this daily Point and Figure chart of DVAX, below, we can see that the software is projecting a potential price target in the $32 area.
 
 
In this fourth chart we used weekly price data and a five-box reversal filter. This Point and Figure chart yields a price target of $70. Not bad! A trade at $25 is a another major breakout on this chart.
 
 
Bottom-line strategy: Aggressive traders could go long DVAX as close to $18 as possible and then risk to $13. The $32 area is our first price target and the $70 is our long-term objective.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Biotechnology | Pharmaceuticals | Mad Money

More from Stocks

Melvin Capital's Demise Presents a Beauty of an Opportunity

Brad Ginesin
May 22, 2022 1:20 PM EDT

The top holder in several companies, the hedge fund's abrupt liquidation has contributed to weakness.

I'm Organizing a Bottom-Fishing Expedition

Bret Jensen
May 22, 2022 11:00 AM EDT

It is easy to see the value of this retail play.

Here's the Secret to Market Timing

James "Rev Shark" DePorre
May 21, 2022 10:00 AM EDT

You've probably been told timing the market is futile, but here's a way to make it possible -- if you're willing to do the work.

It's Official: That Hairy Animal With Claws and Sharp Teeth Is a Bear

James "Rev Shark" DePorre
May 20, 2022 4:31 PM EDT

Along with the media proclamation of a bear market, we have some improvement in the charts of many smaller stocks, but ...

Applied Materials Slips on Miss: Where Will the Chips May Fall

Bruce Kamich
May 20, 2022 1:00 PM EDT

Let's see what the charts say.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An interesting chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login